Verici Dx Past Earnings Performance
Past criteria checks 0/6
Verici Dx's earnings have been declining at an average annual rate of -9%, while the Biotechs industry saw earnings growing at 15.9% annually. Revenues have been growing at an average rate of 150.9% per year.
Key information
-9.0%
Earnings growth rate
10.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 150.9% |
| Return on equity | -245.5% |
| Net Margin | -862.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Verici Dx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -9 | 9 | 0 |
| 30 Sep 23 | 1 | -10 | 9 | 0 |
| 30 Jun 23 | 0 | -11 | 10 | 0 |
| 31 Mar 23 | 0 | -11 | 10 | 0 |
| 31 Dec 22 | 0 | -11 | 10 | 0 |
| 30 Sep 22 | 0 | -11 | 10 | 0 |
| 30 Jun 22 | 0 | -11 | 10 | 0 |
| 31 Mar 22 | 0 | -10 | 8 | 0 |
| 31 Dec 21 | 0 | -8 | 7 | 0 |
Quality Earnings: VRCD.F is currently unprofitable.
Growing Profit Margin: VRCD.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if VRCD.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare VRCD.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VRCD.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: VRCD.F has a negative Return on Equity (-245.48%), as it is currently unprofitable.